DBV Technologies Shares Fall 4.21% Despite a 176% Gain Over One Year
On Tuesday, April 7, the stock of the biotech company specializing in food allergies saw a sharp decline in a generally downward Parisian market. With a price at €3.48, DBV Technologies has erased some of the gains accumulated in recent months, although its performance over one year remains significantly positive at over 176%.
DBV Technologies' stock drops 4.21% from its last close, at €3.48, in an unfavorable environment for healthcare stocks listed in Paris. Sanofi is down 2.22% in the session, while UCB falls by 0.23%. The CAC 40 itself is in negative territory, at 7,924.16 points (-0.48% in session), as is the SBF 120 (-0.48%). Despite this decline, the stock maintains an upward trajectory over longer horizons: it has risen by nearly 16% over three months and shows a gain of more than 176% over one year. The absence of a specific catalyst—neither earnings releases nor identified clinical news today—suggests that the movement is more a reflection of the general market dynamics than an event specific to the company.
Technical Analysis Insights
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical analysis perspective, the price of DBV Technologies, at €3.48, is below its 20-day (€3.59) and 50-day (€3.71) moving averages, indicating a short-term waning of bullish momentum. The stock is trading in the lower part of its Bollinger Bands, at 37% of the range between the lower bound (€3.18) and the upper bound (€3.99), which reflects a relatively low positioning without indicating an oversold situation. The RSI, at 52, remains in a neutral zone, showing neither excessive buying nor marked selling pressure. The nearest support threshold is at €3.37, a level to watch if the decline continues. It is worth noting that the monthly volatility of the stock remains high, at 22.35%, a characteristic typical of biotechnological stocks of this market capitalization.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
